169 related articles for article (PubMed ID: 19934338)
1. EphA2 in the early pathogenesis and progression of non-small cell lung cancer.
Brannan JM; Sen B; Saigal B; Prudkin L; Behrens C; Solis L; Dong W; Bekele BN; Wistuba I; Johnson FM
Cancer Prev Res (Phila); 2009 Dec; 2(12):1039-49. PubMed ID: 19934338
[TBL] [Abstract][Full Text] [Related]
2. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.
Sun Y; Chen C; Zhang P; Xie H; Hou L; Hui Z; Xu Y; Du Q; Zhou X; Su B; Gao W
Sci Rep; 2014 Oct; 4():6527. PubMed ID: 25284075
[TBL] [Abstract][Full Text] [Related]
3. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.
Brannan JM; Dong W; Prudkin L; Behrens C; Lotan R; Bekele BN; Wistuba I; Johnson FM
Clin Cancer Res; 2009 Jul; 15(13):4423-30. PubMed ID: 19531623
[TBL] [Abstract][Full Text] [Related]
4. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.
Yu L; Chen D; Song J
Thorac Cancer; 2020 Mar; 11(3):603-611. PubMed ID: 31953899
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC.
Guo C; Shao R; Correa AM; Behrens C; Johnson FM; Raso MG; Prudkin L; Solis LM; Nunez MI; Fang B; Roth JA; Wistuba II; Swisher SG; Lin T; Pataer A
J Thorac Oncol; 2013 Mar; 8(3):301-8. PubMed ID: 23370317
[TBL] [Abstract][Full Text] [Related]
6. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway.
Ravi J; Sneh A; Shilo K; Nasser MW; Ganju RK
Oncotarget; 2014 May; 5(9):2475-86. PubMed ID: 24811863
[TBL] [Abstract][Full Text] [Related]
7. p190A RhoGAP is involved in EGFR pathways and promotes proliferation, invasion and migration in lung adenocarcinoma cells.
Notsuda H; Sakurada A; Endo C; Okada Y; Horii A; Shima H; Kondo T
Int J Oncol; 2013 Nov; 43(5):1569-77. PubMed ID: 24043274
[TBL] [Abstract][Full Text] [Related]
8. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.
Song W; Ma Y; Wang J; Brantley-Sieders D; Chen J
Cancer Res; 2014 May; 74(9):2444-54. PubMed ID: 24607842
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer.
Zhang H; Duan CJ; Chen W; Wang SQ; Zhang SK; Dong S; Cheng YD; Zhang CF
Asian Pac J Cancer Prev; 2012; 13(5):2355-62. PubMed ID: 22901222
[TBL] [Abstract][Full Text] [Related]
10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
11. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
12. Pathobiological implications of MUC4 in non-small-cell lung cancer.
Majhi PD; Lakshmanan I; Ponnusamy MP; Jain M; Das S; Kaur S; Shimizu ST; West WW; Johansson SL; Smith LM; Yu F; Rolle CE; Sharma P; Carey GB; Batra SK; Ganti AK
J Thorac Oncol; 2013 Apr; 8(4):398-407. PubMed ID: 23370366
[TBL] [Abstract][Full Text] [Related]
13. [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
Zhang W; Zhang W; Wang L; Zheng J; Xiao F
Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):385-90. PubMed ID: 21569641
[TBL] [Abstract][Full Text] [Related]
14. B-Myb Is Up-Regulated and Promotes Cell Growth and Motility in Non-Small Cell Lung Cancer.
Jin Y; Zhu H; Cai W; Fan X; Wang Y; Niu Y; Song F; Bu Y
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555007
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of muscarinic receptor 3 promotes metastasis and predicts poor prognosis in non-small-cell lung cancer.
Lin G; Sun L; Wang R; Guo Y; Xie C
J Thorac Oncol; 2014 Feb; 9(2):170-8. PubMed ID: 24419413
[TBL] [Abstract][Full Text] [Related]
16. High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
Chen C; Peng S; Li P; Ma L; Gan X
Mol Cell Biochem; 2020 Dec; 475(1-2):15-25. PubMed ID: 32761510
[TBL] [Abstract][Full Text] [Related]
17. Ophiopogonin B suppresses the metastasis and angiogenesis of A549 cells in vitro and in vivo by inhibiting the EphA2/Akt signaling pathway.
Chen M; Hu C; Guo Y; Jiang R; Jiang H; Zhou Y; Fu H; Wu M; Zhang X
Oncol Rep; 2018 Sep; 40(3):1339-1347. PubMed ID: 29956803
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
[TBL] [Abstract][Full Text] [Related]
20. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
